Filing identity and reporting period
Important mismatch: The supplied filing is Kintara Therapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2021 (filed May 13, 2021), covering the three and nine months ended on that date. It is not identified in the filing as a Tuhura Biosciences, Inc. filing or as a 2020 Q3 report. Verify the issuer and period before relying on this summary.
Kintara is a clinical-stage oncology company developing VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. It reported no revenue to date. Unless noted otherwise, financial figures below are in thousands of U.S. dollars.
Financial performance and position
| Metric | Three months ended March 31, 2021 | Three months ended March 31, 2020 | Nine months ended March 31, 2021 | Nine months ended March 31, 2020 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $3,843 | $899 | $7,784 | $2,332 |
| General and administrative expense | $2,762 | $1,077 | $7,091 | $3,045 |
| Net loss | $6,635 | $1,957 | $31,566 | $5,303 |
| Loss per share, basic and diluted | $0.23 | $0.17 | $1.47 | $0.52 |
- Nine-month expenses included a $16,094 non-cash charge for acquired in-process R&D and $500 of merger costs. The R&D charge reflects the Adgero asset acquisition and was expensed because the acquired assets had no alternative future use.
- Cash used in operating activities was $14,171 for the nine months, versus $5,350 in the comparable prior period. The company attributed the increase in spending primarily to clinical development, including the GBM AGILE study, REM-001 development, and higher personnel and stock-based compensation costs.
- Cash and cash equivalents were $15,718 at March 31, 2021, versus $2,392 at June 30, 2020. The company reported working capital of $14,055, total assets of $18,853, total liabilities of $2,735, and stockholders’ equity of $16,118.
- Cash provided by financing activities was $26,533 for the nine months, chiefly from approximately $21,598 net proceeds from a Series C preferred-stock placement, $4,399 from warrant exercises, and a $500 loan. Cash increased by $13,326 to $15,718.
- The loan’s carrying amount was $503 at March 31, 2021; the $500 loan bears 6% interest and matures June 19, 2021. The filing states fair value, including principal and accrued interest, was $523.
- Gross margins are not meaningful because the company reported no revenue.
Material changes versus comparable periods
- Quarterly net loss increased to $6,635 from $1,957; nine-month net loss increased to $31,566 from $5,303. The nine-month comparison is materially affected by the $16,094 acquired in-process R&D charge and $500 merger costs.
- Quarterly R&D expense rose to $3,843 from $899, and nine-month R&D expense rose to $7,784 from $2,332, reflecting GBM AGILE startup and enrollment activity, REM-001 development and manufacturing, higher staffing, and stock-based compensation.
- Quarterly G&A expense rose to $2,762 from $1,077; nine-month G&A rose to $7,091 from $3,045. The company cited stock-based compensation, added personnel, insurance, and higher professional fees.
- The August 2020 Adgero merger added REM-001 to the portfolio and materially changed the company’s assets, operations, and capital structure. The company raised $25,000 gross through Series C preferred stock, or approximately $21,598 net, and issued substantial convertible preferred securities and warrants.
Outlook, risks, and unusual items
- Funding and going concern: Management stated that cash was expected to fund planned operations into the second quarter of calendar 2022. However, the filing says additional funding will be required and that substantial doubt exists about the company’s ability to continue as a going concern within one year from the financial statements’ issuance. Planned financing sources include equity and strategic partnerships; success is not assured, and programs may be tailored or delayed if funding is insufficient.
- Clinical outlook: Management expected higher fiscal 2021 R&D spending as GBM AGILE and REM-001 development continued. Listed milestones included VAL-083 recurrent-study top-line results in Q2 2021, adjuvant-study top-line results in Q3 2021, first REM-001 lead-in patient in Q4 2021/Q1 2022, and potential GBM AGILE Stage 1 graduation in the first half of 2022. These are forward-looking expectations, not guarantees.
- Clinical data and safety: Management reported interim VAL-083 results from open-label Phase 2 studies, including median overall survival of 7.5 months in 83 efficacy-evaluable recurrent patients and median progression-free survival of 10.0 months in 33 efficacy-evaluable adjuvant patients. Comparisons cited were historical, not head-to-head trials. Myelosuppression, including thrombocytopenia, was identified as a key VAL-083 safety concern.
- COVID-19: Management said it had not experienced significant disruption to the cited clinical studies, but reported manufacturing and supply delays for REM-001 that could affect its timeline. The pandemic’s impact on future fundraising remained uncertain.
- Contingencies: The company recorded a $202 Level 3 milestone-payment liability related to REM-001, with potential future payments of $300 upon specified development or financing events and $700 upon regulatory approval, subject to agreement terms.
- Capital structure and dilution: Series C preferred shares carry conversion and cumulative share-dividend provisions; the filing recorded a $3,181 non-cash deemed dividend. The company also had substantial outstanding common warrants, preferred-stock conversion rights, and stock options. After quarter-end, the remaining Series B preferred stock converted into common stock.
- Controls: Management concluded disclosure controls and procedures were not effective at period-end because of a material weakness previously reported in the fiscal 2020 Form 10-K. No material change in internal control was reported during the quarter.
- The filing reported no legal proceedings, no defaults upon senior securities, and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm that Kintara Therapeutics and the March 31, 2021 reporting period—not Tuhura Biosciences and 2020 Q3—are the intended issuer and filing.
- Assess the going-concern warning, cash runway assumptions, financing needs, and whether subsequent financing or partnerships were secured.
- Check actual enrollment, results, safety findings, and timelines for GBM AGILE, the VAL-083 Phase 2 studies, and REM-001, including the effect of manufacturing delays.
- Review dilution exposure from Series C conversions and dividends, warrants, stock options, and the post-quarter Series B conversion.
- Evaluate the status and remediation of the disclosed material weakness in disclosure controls.